trending Market Intelligence /marketintelligence/en/news-insights/trending/omgb52gm2lswwizxi2ckpg2 content esgSubNav
In This List

China Regenerative Medicine names CEO/executive director

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


China Regenerative Medicine names CEO/executive director

China Regenerative Medicine International Ltd. said Wang Xuejun will serve as CEO and an executive director, effective Sept. 3.

Wang will also serve as CEO at the company's stem cell division. He replaces Chen Chunguo, who resigned in July. Wang previously held executive roles at Vcanbio Cell & Gene Engineering Corp. Ltd., Union Stemcell & Gene Engineering Co. Ltd. and certain units of Heze Biotechnology Co. Ltd.

Additionally, China Regenerative Medicine appointed Ray Yip to serve as chief medicine officer and Zhang Jinnan as chief technology officer.

Yip joined the company's board in February 2017, and was named an executive director in September that year. Zhang was assistant to CEO of China Regenerative Medicine, and deputy general manager of Shenzhen Ainear Cornea Engineering Co. Ltd.

Hong Kong-based China Regenerative Medicine develops biomedical and healthcare products, as well as medical techniques.